43
Participants
Start Date
August 13, 2018
Primary Completion Date
September 22, 2022
Study Completion Date
September 7, 2023
Ixazomib
Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.
Ixazomib
Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
Ibrutinib
Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
Ibrutinib
Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
Laura and Isaac Perlmutter Cancer Center at NYU, New York
University of Pennsylvania Abramson Cancer Center, Philadelphia
University of Virginia, Charlottesville
West Virginia University, Morgantown
Winship Cancer Institute of Emory University, Atlanta
Georgia Cancer Center at Augusta University, Augusta
ProHealth Care, Waukesha
Medical College of Wisconsin, Milwaukee
University of Wisconsin, Madison
Gundersen Health System, La Crosse
Carle Cancer Center, Urbana
Washington University School of Medicine, St Louis
University of Kansas, Overland Park
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
Takeda
INDUSTRY
PrECOG, LLC.
OTHER